We suspected that the unrestrained sphingolipid biosynthesis caused by ALS-associated SPTLC1 variants might arise from impaired ceramide-mediated SPT-ORMDL inhibition. Here, SPTLC1 is linked to amyotrophic lateral sclerosis.